Cutia Therapeutics Sets 31 Aug 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend
Bulletin Express
Aug 19
Cutia Therapeutics has scheduled a board meeting for 31 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026, consider recommending an interim dividend, and address other routine matters.
The board currently comprises two executive directors, four non-executive directors, and three independent non-executive directors. The session will be chaired by Chief Executive Officer and Executive Director Zhang Lele.
The company plans to release its interim financial results to the market following board approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.